Pilot study of flesinoxan, a 5‐HT1A agonist, in major depression: Effects on sleep REM latency and body temperature

@article{Ansseau1993PilotSO,
  title={Pilot study of flesinoxan, a 5‐HT1A agonist, in major depression: Effects on sleep REM latency and body temperature},
  author={Marc Ansseau and William Pitchot and Antonio Gonzalez Moreno and Jacques Wauthy and Patrick Papart},
  journal={Human Psychopharmacology: Clinical and Experimental},
  year={1993},
  volume={8}
}
Flesinoxan is a highly potent and selective 5‐HT1A full agonist, active in several models of depression. In this pilot open study, flesinoxan (4 mg/d) was administered orally for 4 weeks in 16 major depressive, mostly treatment‐resistant inpatients exhibiting a score of at least 19 on the Hamilton depression sale. Weekly ratings included Hamilton depression scale, Montgomery and Asberg depression scale (MADRS), and Clinical Global Impressions (CGI). Results showed considerable improvement in… Expand
The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat
TLDR
Both doses of flesinoxan significantly reduced the immobility time in the sham and OB groups when compared to their respective controls, and significantly attenuated the 8-OH-DPAT-induced hypothermic response. Expand
5‐HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response
TLDR
It is concluded that selective targeting of 5‐HT receptors may lead to a faster acting and more efficient antidepressant response. Expand
Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
TLDR
In agreement with pharmacological studies, presynaptic and postsynaptic 5- HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT 1A-Rs are also involved. Expand
The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects.
TLDR
The data show that the anxiolytic effects of flesinoxan in the shock-probe burying paradigm are not related to increases in plasma corticosterone and glucose levels. Expand
Characterization of 5-hydroxytryptamine1A properties of flesinoxan: In Vivo electrophysiology and hypothermia study
TLDR
The flesinoxan-induced hypothermia was significantly attenuated by prior administration of the non-selective 5-HT1A antagonist pindolol and the 5- HT1/2 antagonist methysergide, suggesting that it may be an effective anxiolytic/ant antidepressant agent. Expand
Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission
TLDR
As for selective 5- HT re-uptake inhibitors, monoamine oxidase inhibitors and 5-HT1A receptor agonists, flesinoxan produced most of the adaptive changes exerted by these antidepressant drugs on the 4-HT system and the marked potency and the long dissociation constant of fles inoxan for the 5-ht1A receptors may account for the latter discrepancy. Expand
Chapter 1. Toward Third Generation Antidepressants
Publisher Summary In second generation anti-depressants, new tricyclics (TCAs), such as maprotiline and atypical agents, like mianserin, are used to reduce the cardiovascular and anti-cholinergicExpand
Chapter 23 Antidepressant and anxiolytic drugs
TLDR
This chapter focuses on antidepressant and anxiolytic drugs, and benzodiazepines are generally accepted to be efficacious in the treatment of GAD. Expand
The corticosterone-enhancing effects of the 5-HT1A receptor antagonist, (S)-UH301, are not mediated by the 5-HT1A receptor.
TLDR
It is concluded that (S)-UH301 is a potent 5-HT1A receptor antagonist and that the (S) UH301-induced corticosterone secretion is mediated by a non-5-HT 1A receptor mechanism. Expand
5‐HT1A Receptor Agonist Flesinoxan Enhances Fos Immunoreactivity in Rat Central Amygdala, Bed Nucleus of the Stria Terminalis and Hypothalamus
TLDR
Investigation of immunoreactivity for the immediate early gene protein product Fos (Fos‐ir) in rat brains 1 h after flesinoxan treatment suggests the involvement of corticotropin‐releasing hormone (CRH) or vasopressin in the hypothalamus, which suggests its activating effects on the HPA axis via CRH neurons in the PVN. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 15 REFERENCES
Ipsapirone: evidence for efficacy in depression.
TLDR
The efficacy results for patients with the diagnosis of neurotic depression were similar for the intent-to-treat population, and safety and tolerability were evaluated for all study patients independent of diagnosis. Expand
Buspirone in depressed outpatients: a controlled study.
TLDR
Buspirone was found to be safe and well-tolerated by patients with major depression and concomitant anxiety at doses of up to 90 mg/day. Expand
REM latency: a psychobiologic marker for primary depressive disease.
  • D. Kupfer
  • Psychology, Medicine
  • Biological psychiatry
  • 1976
TLDR
It is indicated that short REM latency is found in virtually all primary depressive illness and is absent in secondary depression, and it is argued that the phenomenon is independent of age, drug effect and changes in other sleep parameters. Expand
Internight variability of REM latency in major depression: Implications for the use of REM latency as a biological correlate
TLDR
The use of the shortest REM latency from at least 3 consecutive nights yielded a higher sensitivity than did the use of any one individually specified night (50%-56%) or different internight means (49%-52%). Expand
Explorative single‐blind study on the sedative and hypnotic effects of buspirone in anxiety patients
TLDR
It is concluded that buspirone does not have a sedative or hypnotic effect in anxiety patients and sleep structure was minimal and of no clinical consequence. Expand
A new depression scale designed to be sensitive to change.
TLDR
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change. Expand
REM latency in depression: is there one best definition?
TLDR
The range of sensitivities yielded by different definitions was narrower and not clearly affected by sleep-onset criterion or exclusion/inclusion of wakefulness between sleep onset and first REM period, and the shorter REM latencies in both outpatients and inpatients were associated with a later time of NREM sleep onset than in controls. Expand
Sleep and treatment prediction in endogenous depression.
TLDR
In 34 drug-free patients with primary endogenous depression treated with amitriptyline, the application of EEG-monitored sleep criteria alone was more significant than clinical status alone in the prediction of clinical response. Expand
Antidepressants and EEG sleep: search for specificity.
TLDR
The EEG sleep profile in de-pressed patients improves the diagnostic classification of affective states, offers an objective set of indicators in assessing the severity of illness, and provides an aid to the choice and length of treatment. Expand
A RATING SCALE FOR DEPRESSION
  • M. Hamilton
  • Psychology, Medicine
  • Journal of neurology, neurosurgery, and psychiatry
  • 1960
TLDR
The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information. Expand
...
1
2
...